Idioma:

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, Stephen D ; Raz, Itamar ; Bonaca, Marc P ; Mosenzon, Ofri ; Kato, Eri T ; Cahn, Avivit ; Silverman, Michael G ; Zelniker, Thomas A ; Kuder, Julia F ; Murphy, Sabina A ; Bhatt, Deepak L ; Leiter, Lawrence A ; McGuire, Darren K ; Wilding, John P.H ; Ruff, Christian T ; Gause-Nilsson, Ingrid A.M ; Fredriksson, Martin ; Johansson, Peter A ; Langkilde, Anna-Maria ; Sabatine, Marc S

The New England journal of medicine, 2019-01, Vol.380 (4), p.347-357 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Autor: Wiviott, Stephen D ; Raz, Itamar ; Bonaca, Marc P ; Mosenzon, Ofri ; Kato, Eri T ; Cahn, Avivit ; Silverman, Michael G ; Zelniker, Thomas A ; Kuder, Julia F ; Murphy, Sabina A ; Bhatt, Deepak L ; Leiter, Lawrence A ; McGuire, Darren K ; Wilding, John P.H ; Ruff, Christian T ; Gause-Nilsson, Ingrid A.M ; Fredriksson, Martin ; Johansson, Peter A ; Langkilde, Anna-Maria ; Sabatine, Marc S
Assuntos: adverse effects ; Aged ; Animal biology ; Antidiabetics ; Arteriosclerosis ; Benzhydryl Compounds ; Benzhydryl Compounds - adverse effects ; Benzhydryl Compounds - therapeutic use ; Cardiovascular disease ; Cardiovascular Diseases ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Cellular Biology ; Cerebral infarction ; Clinical Medicine ; complications ; Congestive heart failure ; Death ; Diabetes ; Diabetes Mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic ketoacidosis ; Drug therapy ; End-stage renal disease ; epidemiology ; etiology ; FDA approval ; Female ; Food and Nutrition ; Glomerular filtration rate ; Glucosides ; Glucosides - adverse effects ; Glucosides - therapeutic use ; Heart attacks ; Heart Failure ; Heart Failure - epidemiology ; Heart rate ; Hospitalization ; Hospitalization - statistics & numerical data ; Humans ; Ischemia ; Ketoacidosis ; Kidney diseases ; Klinisk medicin ; Life Sciences ; Male ; Middle Aged ; Mortality ; Myocardial infarction ; Patients ; Pharmaceutical sciences ; prevention & control ; Safety ; Sodium ; Sodium-glucose cotransporter ; Sodium-Glucose Transporter 2 Inhibitors ; Sodium-Glucose Transporter 2 Inhibitors - adverse effects ; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use ; statistics & numerical data ; therapeutic use ; Type 2
É parte de: The New England journal of medicine, 2019-01, Vol.380 (4), p.347-357
Descrição: In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher or lower rate of cardiovascular death, myocardial infarction, or stroke than placebo but did result in a lower rate of hospitalization for heart failure.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.